SITC 2017 Abstract Titles – Case Studies demonstrating exceptional responses or best practices for management of irAEs

#

Title

Authors

Affiliations

Keywords

P440

Durable Complete Response with PANVAC and Trastuzumab in Metastatic Triple Positive Breast Cancer (mTPBC)

Margaret Gatti-Mays¹, Mahsa Mohebtash², Ravi Madan¹, Julius Strauss¹, Marijo Bilusic¹, Caroline Jochems¹, Myrna Rauckhorst¹, Elizabeth Jones³, William Dahut¹, Jeffrey Schlom¹, James Gulley¹

¹National Cancer Institute, NIH, Bethesda, MD, USA ²Medstar Union Memorial Hospital, Baltimore, MD, USA ³National Institutes of Health, Bethesda, MD, USA

Costimulation | Immune adjuvant | Solid tumors | Chemotherapy | Clinical trial | Vaccine

P441

Activity of Nivolumab (Opdivo®) in relapsed progressive peripheral T-cell Lymphoma-NOS (PTCL-NOS)

Philip A Haddad¹, David Sommerhalder²

¹Overton Brooks VAMC, Shreveport, LA, USA ²LSUHSC-S, Shreveport, LA, USA

Leukemia/Lymphoma | Checkpoint blockade | T cell

P442

Pseudoprogression manifesting as recurrent ascities with anti-PD-1 therapy

Randy Sweis¹, Yuanyuan Zha¹, Russell Szmulewitz¹, Lomax Pass¹, Tara Chongsuwat¹, Jason Luke¹, Thomas Gajewski¹

¹University of Chicago, Chicago, IL, USA

Inflammation | Checkpoint blockade | Immune toxicity | Solid tumors | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | T cell

P443

Malignant melanoma metastatic to the heart: exploring patient outcomes and cardiovascular complications in the era of immunotherapy

Laura Talamo¹, William Grosh¹

¹University of Virginia, Charlottesville, VA, USA

Checkpoint blockade | Targeted therapy